Climate Change Data

上海医药集团股份有限公司

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Not disclosed

Social Achievements

  • Launched a rare disease platform, Shangyao Ruer, with 16 projects underway.
  • Published the nation's first ESG information disclosure guideline for the pharmaceutical industry.

Governance Achievements

  • Successfully completed the change of the board of directors, supervisors and senior management.
  • MSCI and Wind ESG ratings of AA, indicating leading position in the global industry.

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • The Chinese pharmaceutical industry is undergoing profound adjustments.
  • One-time special gains and losses impacted net profit.
Mitigation Strategies
  • Implemented a “steady growth, improved efficiency, risk control, and optimized system” strategy.
  • Focused on innovation, integration, and internationalization.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Not disclosed

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Fortune Global 500, Global Top 50 Pharmaceutical Companies, Global Top 25 Most Valuable Pharmaceutical Brands, China's Top 100 Pharmaceutical Companies, Best Industrial Enterprise for Pharmaceutical R&D Product Lines in China, Asia-Pacific Quality Organization Innovation Award (Star)